Epicardial Adipose Tissue Thickness and its Corelation with Metabolic Risk Parameters in People Living with HIV: A RIMS Study

S. Bhagyabati Devi, Keisham J. Chanu, T. Jeetenkumar, H. Lalrinfela, Priscilla C. Lalmchhuani, Tutan Das
Department of Medicine, Regional Institute of Medical Sciences (RIMS), Imphal, Manipur, India

Abstract

Context: Epicardial fat envelopes the coronary vessel adventitia without fascial separation, thus pathologic inflammation in the fat may promote the growth of atherosclerotic plaque in coronary arteries in an ‘outside-in’ fashion. Epicardial fat is quantitatively increased in HIV compared to un-infected people. Aims: 1. To assess Epicardial Adipose tissue (EAT) by Computed tomography (CT) in PLHIV receiving first line ART (antiretroviral therapy) 2. To correlate EAT with metabolic risk parameters. Material and Methods: 215 HIV-infected patients aged >18 years on first line ART were included in the cross sectional study. EAT thickness were measured by CT scan. Metabolic parameters were measured based on metabolic syndrome criteria. Statistical Analysis Used: Data analysis was done using IBM SPSS version ver. 21. Probability value of less than 0.5 was taken as significant. Ethical Issues: The study was carried out after obtaining approval from the Institutional Ethical Committee (IEC), Regional Institute of Medical Sciences, Imphal. Results: Half of the patients were found to have EAT thickness of 8.1-9 mm and 12.6% of cases had EAT of >9 mm. Mean epicardial thickness was 8.3 mm ± 0.7 mm for whole population. Triglyceride and high density lipoprotein (HDL) were also found to have positive correlation with EAT thickness (r_p = 0.364, P = 0.04 and r_p = 0.343, P = 0.05 respectively). Conclusion: Epicardial adipose tissue thickness is increased in PLHIV receiving highly active anti retroviral therapy (HAART) and positively co-related with parameters of metabolic syndrome such as waist circumference, HDL cholesterol and triglyceride level.

Keywords: Epicardial adipose tissue, HAART, metabolic parameters, PLHIV, visceral adipositis

INTRODUCTION

Individuals infected with human immunodeficiency virus (HIV) are at increased risk of cardiometabolic complications. The pathophysiological basis for such a higher risk is complex; some could be related to HIV disease process and others could be related to treatment with antiretroviral drugs. The use of antiretroviral therapy (ART) is accompanied by expanding or altered visceral fat depots, which are metabolically active and harbor an inflammatory milieu that contribute to insulin resistance and promotes atherosclerosis.

Metabolic syndrome (MetS) includes visceral adiposity, which is closely associated with diabetes, dyslipidemia, hypertension, and cardiovascular disease. The relationship between waist circumference and intraabdominal obesity or visceral adipose tissue (VAT) depends on age, gender, and ethnicity. Epicardial adipose tissue (EAT) is the fat located between the myocardium and visceral pericardium. Because EAT and VAT share the same embryological origin from the splanchnopleuric mesoderm, it is conceivable that EAT may be as strong a risk marker of cardiovascular disease as VAT. Though EAT has been linked with incident cardiovascular events in the general population, there is paucity of studies that assess the role of EAT as a cardiometabolic risk marker in patients with HIV.

Aims and objectives

1. To assess EAT by computed tomography (CT) in PLHIV receiving first line ART
2. To correlate EAT with metabolic risk parameters.

Address for correspondence: Dr. Keisham J. Chanu, Department of Medicine, Regional Institute of Medical Sciences (RIMS), Imphal, Manipur, India. E-mail: jayakeisham@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Devi BS, Chanu KJ, Jeetenkumar T, Lalinfela H, Lalmchhuani PC, Das T. Epicardial adipose tissue thickness and its correlation with metabolic risk parameters in people living with HIV: A RIMS study. Indian J Endocr Metab 2018;22:641-4.
SUBJECTS AND METHODS

This cross-sectional study was conducted in 215 HIV-infected patients admitted to medicine ward or registered in ART center, Regional Institute of Medical Sciences (RIMS), Imphal, from October 2014 to September 2016.

Inclusion criteria: Both male and female patients of age >18 years on first line ART regime.

Exclusion criteria: Patients with history of smoking, diabetes, hypertension, cardiovascular diseases, BMI >29 kg/m², patient on stavudine or abacavir, statins, fibrates, and patients not willing to participate.

The patients were provided with written-informed consent. For all eligible participants a detailed history with emphasis on drug adherence, drug history, and duration on first-line therapy was taken and underwent thorough clinical examination, routine laboratory tests according to NACO guideline.

The quantification of EAT thickness was done using plain CT thorax by Brilliance 64, Phillips machine (64-slice multidetector CT). CT scan of the cardiac region extended from carina to inferior border of the heart. Thick slice (5-mm thick slices) axial images of the cardiac scan were analyzed for the epicardial fat, which have attenuation value of −30 to −200 Hounsfield units (HU). Using freehand ROI (region of interest tool) tool, the epicardial fat were outlined manually on the workstation and the surface area covered was recorded for each single thick slice axial images. Epicardial fat volume of each thick slice was calculated by multiplying the surface area of the epicardial fat by a factor of 5 mm. The epicardial fat volume of the thick slices was then summated to yield the total epicardial fat volume.

Anthropometric measurement was done by measuring height (centimeters) and weight (kilograms) with subject wearing light clothing and no shoes. BMI (kilogram per square meter) was calculated. Waist circumference was assessed at the midpoint between 12th rib and the iliac crest. Serum lipid profile (total cholesterol, high density and low-density lipoproteins, and triglyceride) and fasting blood glucose levels were measured using standard techniques. CD4 cell counting was done by flow cytometry (FACS count).

The study was carried out only after obtaining approval from the Institutional Ethics Committee (IEC), Regional Institute of Medical Sciences.

Statistical analysis: Data analysis was done using IBM SPSS version ver. 21. Data were described using mean and percentages. Test of significance was done using chi square test, t-test, and ANOVA. Probability value of less than 0.5 was taken as significant.

RESULTS

Majority of the patients were from the age group 40–49 years. Mean age was 38.3 years with a standard deviation of 9.6 years. Three fourth of the respondents were males (75.8%) as compared to females (24.2%). Among 215 patients, 153 patients were taking TLE (71.2%) and 62 were taking...
ZLN (28.8%). Majority of the patients had been on ART treatment for 1–5 years (41.6%) and maximum of the patients were found to have a CD4 count of more than 300 cells/cumm (70.6%).

Most of the patients had normal BMI (69.3%) in the range of 18.5–24.9 kg/m², 14.4% were overweight whereas 6.5% of patients fall in the obesity range (30 kg/m² or higher). Females had more number of overweight (47.4% vs 3.6%) and obesity (7.5% vs 7.3%) patients than males and the finding was statistically significant ($P < 0.05$). Abdominal waist circumference was significantly more in females than males (107.2 ± 11.0 cms vs 104.5 ± 9.7 cms, $P = 0.01$). We found that 6.2% of the patients were found to have fasting blood glucose above 100 mg/dl ($P = 0.126$, insignificant) and 6.6% of them have BP above 130/85 mmHg ($P = 0.23$, insignificant).

In our study, half of the patients were found to have EAT thickness of 8.1–9 mm. EAT thickness of >9 mm was found in 12.6% of cases. Mean epicardial thickness was 8.3 mm for whole population with a standard deviation of 0.7 mm. Patients with age above 50 years had increased EAT thickness than others age group (8.7 ± 1.1 mm). The finding was statistically significant ($P < 0.05$). Females had an increased EAT thickness compared to males in our study (8.9 ± 0.7 mm vs 8.1 ± 0.5 mm) [Tables 1 and 2].

However, our study found a negative correlation between EAT thickness and BMI ($r_p = -0.076$) and the finding was statistically insignificant ($P > 0.05$). With the increase in CD4 count there was increase in EAT thickness ($r_p = -0.029$) and vice versa and the finding was significant ($P < 0.05$). Triglyceride and HDL were also found to have positive correlation with EAT thickness ($r_p = 0.364$, $P = 0.04$ and $r_p = 0.343$, $P = 0.05$, respectively). There was a poor correlation between cholesterol level and EAT thickness ($r_p = 0.004$, $P = 0.952$). There was a negative correlation between duration of ART and EAT thickness ($P = 0.265$). Patient who were on ZLN had increased EAT thickness than patient on TLE (8.4 ± 0.9 vs 8.3 ± 0.6) but the finding was insignificant ($P = 0.1$).

**Discussion**

EAT and VAT share the same embryonic origin.[5] The adipose tissue releases adiponectins, a protein hormone involved in free fatty acids and glucose metabolism. Increased production of proinflammatory cytokines like cytokines-1, 6, TNFα, and resistin in obesity interfere with the production of novel adiponecin resulting in hyperinsulinemia and MetS.[6]

HIV infection as well as HAART increase deposition of adipose tissue in the abdomen and epicardium with simultaneous wasting of hip and thigh due to mixed lipodystrophy, which is more clearly observed in females than male. Longer the duration of ART (>5 years), more is the lipodystrophy. It is also correlated with the level of CD4 T-cells as T-lymphocytes are increased in the adipose tissue of obese PLHIV.[7] In our study of 215 cases, majority of the respondents were from age group 40–49 years with a mean age of 38.3 years. Three by fourth of them were males as more number of males were registered during the study period (M: F = 1.3:1). More than half (TLE-71.2% vs ZLN-28.8%) of population were on TLE as per revised guidelines of NACO (2014). A total of 39.5% of them was on ART for more than 5 years with a CD4 count above 300 mm² (70.6%) showing the effectiveness of HAART in immunomodulation, improvement of immunity, and prolongation of life expectancy.

Measurement of EAT thickness gave an increase in value in 50% (8.1–9 mm) and >9 mm in 12.6%, rest (37.4%) had normal thickness (7.18 mm). Age above 50 years, population had thicker EAT ($P = 0.05$) compared to younger population. It can be explained by the fact that ageing process leads to decrease in lean body mass and increase in the visceral fat thereby producing more of metabolic changes. With the increase of CD4 T-cell count, there was increase in EAT thickness and vice versa ($P = 0.05$). A study by Brener Malso found the association between current CD4 T-cell count and cumulative exposure to HAART with EAT.[8] Mariana Diaz-Zamudio stated that increased EAT thickness among HIV-infected cases are related to duration of HIV infection and HAART exposure. They found that presence of clinical lipoaccumulation is secondary to HAART and not due to chronologic age of the patient.[7] The direct ART toxicity, which is the result of metabolic alterations induced by these therapies, and/or the potential pathological effects of immune-reconstitution may express itself as EAT. T-lymphocytes are increased in the adipose tissue following HIV infection and ART treatment. These reconstituted CD4 lymphocytes may behave in a proinflammatory and proatherogenic way rather than being solely protective.[9] In our study, patients receiving ZLN were found to have higher value of EAT that is in conformity with study by Brenner et al.[9]

The result of mean EAT in males was 8.1 ± 0.5 mm and in females 8.9 ± 0.7 mm in our study that is contradicted to the finding by Guaraldi et al. and Iacobellis et al. and in conformity with Torriani et al.[5,10,11] According to Torriani et al., HIV-infected females are associated with more frequency of fat redistribution and metabolic abnormalities leading to increased fat accumulation in EAT and visceral fat.[11] In our study, females had more number of overweight (47.4% vs 3.6%) and obesity (7.5% vs 7.3%) compared to males and the finding was statistically significant ($P = 0.05$). There was a negative correlation between EAT and BMI ($P = 0.265$) that is in contrast with Brenner M et al. and in conformity with Lo et al. that can be explained by late initiation of HAART (NACO guideline) in our population as compared to western countries producing earlier and higher degree of lipodystrophy and also may be as a result of malnutrition seen commonly in this group of population.[8,12]

Abdominal waist circumference was significantly more in females than males (107.2 ± 11 vs 104.5 ± 9.7) having a
Devi, et al.: Epicardial adipose tissue thickness and its correlation with metabolic risk parameters in people living with HIV: A RIMS study

$P$ value of 0.01. According to our study, there was HIV-related dyslipidemia with elevated triglyceride with decreased HDL, which is in conformity to the study done by Riddler et al.\textsuperscript{[13]} We did not find association of EAT with blood glucose and blood pressure in our population. In our study, 6.2% of the patients were found to have fasting blood glucose above 100 mg/dl ($P = 0.126$, insignificant) and 6.6% of them had BP above 130/85 mmHg ($P = 0.23$, insignificant). This could mean that our population are less prone to alterations in glucose metabolism and hypertension compared to the western population.

**Conclusion**

EAT thickness is increased in PLHIV receiving HAART (first line). EAT is positively correlated with parameters of MetS such as waist circumference, HDL cholesterol, and triglyceride level. Thus, EAT measurement among HIV cases can be considered as a reliable method of assessing cardiovascular risk among patients receiving HAART.

**Limitations**

This is a single center-based cross-sectional study, thus we are able to establish only the association of EAT and HAART. Shorter duration of follow-up might be affected by the survival bias. We might be missing considerable number of patients died before the initiation of our study who might have significant EAT thickness. Community-based cohort study including controls from general population for comparison will give a better result.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
2. Grunfeld C, Saug M, Cofrancesco J Jr, Lewis CE, Kronmal R, Heymsfield S, et al. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). AIDS 2010;24:1717-26.
3. Sagun G, Aytekin O, Karagöz E, Filizer AT, Tamer G, Mesci B. Application of alternative anthropometric measurements to predict metabolic syndrome. Clinics 2014;69:347-53.
4. Sacks HS, Fain JN. Human epicardial adipose tissue: A review. Am Heart J 2007;153:907-17.
5. Guaraldi G, Scaglioni R, Zona S, Orlando G, Carli F, Ligabue G, et al. Epicardial adipose tissue is an independent marker of cardiovascular risk in HIV-infected patients. AIDS 2011;25:1199-205.
6. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: Action, regulation and association to insulin sensitivity. Obes Rev 2005;6:13-21.
7. Diaz-Zamudio M, Dey D, LaBounty T, Nelson M, Fan Z, Lidia S, et al. Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: A 3T cardiovascular magnetic resonance feasibility study. J Cardiovasc Magn Res 2015;17:91
8. Brener M, Ketrogetsw S, Budoff M, Jacobson LP, Li X, Rezaeian P, et al. Epicardial Fat is Associated with Duration of Antiretroviral Therapy and Coronary Atherosclerosis: The Multicenter AIDS Cohort Study. AIDS 2014;28:1635-44.
9. Guaraldi G, Zona S, Alexopoulos N, Orlando G, Carli F, Ligabue G, et al. Coronary aging in HIV-infected patients. Clin Infect Dis 2009;49:1756-62.
10. Iacobellis G, Sharma AM, Pellicelli AM, Grisorio B, Barbarini G, Barbaro G. Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. Curr HIV Res 2007;5:275-9.
11. Torriani M, Thomas BJ, Barlow RB, Librizz J, Dolan S, Grinspoon S. Increased intramyocellular lipid accumulation in HIV-infected women with fat redistribution. J Appl Physiol 2006;100:609-14.
12. Lo J, Abbara S, Rocha-Filho JA, Shurtman L, Wei J, Grinspoon SK. Increased Epicardial Adipose Tissue Volume in HIV-Infected Men and Relationships to Body Composition and Metabolic Parameters. AIDS 2010;24:2127-30.
13. Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 2007;8:280-7.